Business Development & Licensing


Vigorous Activities for Licensing Initiatives

We continue to forge ahead with licensing activities to introduce new drug candidates with the aim of introducing compounds attractive for diseases with high therapeutic need, and compounds that have high value in terms of corporate strategy and efficiency, while taking into consideration the development pipeline and existing products. Our aim is to expand the development pipeline to provide a continuous stream of new market launches. In 2014, we signed a strategic collaboration agreement with Bristol-Myers Squibb Company (BMS) regarding immuno-oncology therapies, and a development collaboration agreement with Kyowa Hakko Kirin and BMS regarding immuno-oncology therapies.
We are simultaneously directing efforts into out-licensing to overseas alliance companies so that patients around the world can use the new drugs we discover. In 2014, we signed a out-licensing and joint development agreement with Gilead Sciences (U.S.A.) regarding BTK inhibitor ONO-4059, and collaboration agreements with Meiji Seika Pharma and China Chemical & Pharmaceutical regarding development and commercialization of the oral prostaglandin E1 analogue Limaprost.
Continuously promoting vigorous licensing activities, we are making steady progress in expanding development pipeline and developing a road map for global business to deliver new drugs we develop.